 |
 |
 |
 |
 |
|
|||||
|
Select Publications
Armstrong DK et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354(1):34-43. Abstract
Gordon AN et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: Results from a phase II multicenter study. Int J Gynecol Cancer 2005;15(5):785- 92. Abstract
Gordon MS et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006;24(26):4324-32. Abstract
Kaye SB et al. A randomised phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab (P) versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Proc ASCO 2008;Abstract 5520.
Makhija S et al. Results from a phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. Proc ASCO 2007;Abstract 5507.
McGuire WP et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334(1):1-6. Abstract
| Table of Contents | Top of Page |
EDITOR
Neil Love, MD
INTERVIEWS
Tate Thigpen, MD
- Select publications
Ursula A Matulonis, MD
- Select publications
Robert A Burger, MD
- Select publications
Bradley J Monk, MD
- Select publications
Ovarian Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
  |
